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Abstract
Background: We explored the mechanisms of cell death induced by isochaihulactone treatment in LNCaP cells.
Methods: LNCaP cells were treated with isochaihulactone and growth inhibition was assessed. Cell cycle profiles
after isochaihulactone treatment were determined by flow cytometry. Expression levels of cell cycle regulatory
proteins, caspase 9, caspase 3, and PARP were determined after isochaihulactone treatment. Signaling pathway was
verified by inhibitors pre-treatment. Expression levels of early growth response gene 1 (EGR-1) and nonsteroidal
anti-inflammatory drug-activated gene 1 (NAG-1) were determined to investigate their role in LNCaP cell death.
NAG-1 expression was knocked down by si-NAG-1 siRNA transfection. Rate of cell death and proliferation were
obtained by MTT assay.
Results: Isochaihulactone caused cell cycle arrest at G2/M phase in LNCaP cells, which was correlated with an
increase of p53 and p21 levels and downregulation of the checkpoint proteins cdc25c, cyclin B1, and cdc2. Bcl-2
phosphorylation and caspase activation were also observed. Isochaihulactone induced phosphorylation of c-Jun-N-
terminal kinase (JNK), and JNK inhibitor partially reduced isochaihulactone-induced cell death. Isochaihulactone also
induced the expressions of EGR-1 and NAG-1. Expression of NAG-1 was reduced by JNK inhibitor, and knocking
down of NAG-1 inhibited isochaihulactone-induced cell death.
Conclusions: Isochaihulactone apparently induces G2/M cell cycle arrest via downregulation of cyclin B1 and cdc2,
and induces cellular death by upregulation of NAG-1 via JNK activation in LNCaP cells.
Background
Prostate cancer is the most common malignancy in
American men and the second leading cause of deaths
from cancer [1]. In the early stage, prostate cancer
usually grows slowly and remains confined to the gland,
initially producing few or no symptoms. As the cancer
advances, it can, however, spread beyond the prostate
into the surrounding tissues and to other areas, such as
the bones, lungs, and liver. Therefore, symptoms often
appear after the cancer has processed to an advanced
stage.
The treatment options for patients with prostate can-
cer include surgery, radiation therapy, hormonal ther-
apy, chemotherapy, cryotherapy, and combinations of
some of these treatments. At the early stage, surgery,
radiation therapy, and hormonal therapy are the pre-
ferred treatments. As the cancer processes, chemother-
apy and cryotherapy become the preferred treatments.
One of the most common drug classes for chemother-
apy treatments for prostate cancer is the taxanes, which
include the first-generation drug paclitaxel (Taxol, a tra-
demark of Bristol-Myers Squibb) [2,3]. Because taxanes
often cause significant negative side effects, newly devel-
oped drugs are valuable.
Recently, non-traditional treatments such as herbs and
dietary supplements have been considered as alternative
medicines. Nan-Chai-Hu (Chai Hu of the South), the
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any medium, provided the original work is properly cited.root of Bupleurum scorzonerifolium,i sa ni m p o r t a n t
Chinese herb in the treatment of influenza, fever,
malaria, cancer, and menstrual disorders in China,
Japan, and many other parts of Asia. We previously
showed that the crude acetone extract of B. scorzonerifo-
lium (BS-AE) causes cell cycle arrest at the G2/M phase
and apoptosis in the human lung carcinoma cell line
A549 [4-6]. After the acetone extract fraction was
further purified, a novel lignan, isochaihulactone, which
has antitumor activity against A549 cells in vitro and in
vivo, was identified [7]. Isochaihulactone induces G2/M
arrest and apoptosis in cancer cells. This compound can
also be isolated from Bursera microphylla (Burseraceae)
and shows antitumor effects [8].
Here we describe the anti-tumor activity of isochai-
hulactone, which causes cell cycle arrest at G2/M
phase and cell death in LNCaP cells. We provided evi-
dence that the disruption of the cell cycle at G2/M
phase and the activation of phospho-Bcl-2 and cas-
pase-3 are important in isochaihulactone-induced cell
death. Recently, we found isochaihulactone induces
growth inhibition and apoptosis in A549 cells by acti-
v a t i n ge a r l yg r o w t hr e s p o n s eg e n e1( E G R - 1 )a n dn o n -
steroidal anti-inflammatory drug-activated gene 1
(NAG-1) through an extracellular signal-regulated
kinase 1/2 (ERK 1/2)-dependent pathway, but PI3K
signaling is not involved [9]. Here we show that iso-
chaihulactone induced growth inhibition and cell death
in prostate cancer cells by activating EGR-1 and NAG-
1 through JNK-dependent pathway and that did not
involve activation of ERK signaling. Also, isochaihulac-
tone-induced cell death can be restored by siNAG-1
siRNA transfection. Our findings indicate that isochai-
hulactone is a potential antitumor compound for pros-
tate cancer therapy.
Methods
Cells and cell culture
LNCaP human prostate cells, obtained from ATCC
(American Type Culture Collection, Manassas, VA),
were cultured in RPMI 1640 medium with 10% heat-
inactivated fetal bovine serum, 100 U/ml penicillin and
100 U/ml streptomycin, 1% sodium pyruvate, 2 mM L-
glutamine (all of these reagents are from Invitrogen,
Carlsbad, CA) at 37°C in a humidified atmosphere with
5% CO2. Cells were plated in 6-well plates at a seeding
density of approximately 2 × 10
5 cells/well in the pre-
sence or absence of isochaihulactone (20 μM).
Chemicals and reagents
Bupleurum scorzonerifolium roots were supplied by
Chung-Yuan Co. (Taipei, Taiwan). The plant was identi-
fied and deposited at National Defense Medicinal Center
(NDMCP No. 900801). Isochaihulactone (4-benzo[1,3]
dioxol-5-ylmethyl-3-(3,4,5-trimethoxyl-benzylidene)-
dihydro-furan-2-one) was prepared as described pre-
viously [7]. RPMI 1640 medium, fetal bovine serum
(FBS), penicillin, streptomycin, L-glutamine, sodium pyr-
uvate, trypsin/EDTA were purchased from Invitrogen.
The RNA isolation kit was purchased from QIAGEN
(Valencia, CA). Dimethyl sulfoxide (DMSO), 3-(4,5-
dimethyl thizol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT), paclitaxel, and horseradish peroxidase-conju-
gated secondary antibodies were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). The ERK1/2 kinase
inhibitor PD98059 and the JNK inhibitor SP600125
were purchased from R&D Systems (Minneapolis, MN).
The p38 inhibitor SB203580 and the PI3K/AKT inhibi-
tor LY294002 were purchased from Calbiochem (San
Diego, CA). The annexin-V-FLUOS Staining Kit was
from Roche Molecular Biochemicals (Mannheim, Ger-
many). Polyvinyldenefluoride (PVDF) membranes, BSA
protein assay kit and western blot chemiluminescence
reagent were purchased from Amersham Biosciences
(Arlington Heights, IL).
Western blot analysis
LNCaP cells were lysed on ice with 200 μl of lysis buffer
(50 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM MgCl2,
0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl fluori-
defor, 1 μg/ml pepstatin, and 50 μg/ml leupeptin) and
centrifuged at 13,000 × g at 4°C for 5 min. The protein
concentrations in the supernatants were quantified
using a BSA Protein Assay Kit. Electrophoresis was per-
formed on a NuPAGE Bis-Tris Electrophoresis System
using 30 μg of reduced protein extract per lane.
Resolved proteins were then transferred to PVDF mem-
branes. Membranes were blocked with 5% non-fat milk
for 1 h at room temperature and probed with appropri-
ately dilution of primary antibodies at 4°C overnight:
NAG-1/PTGF-b (1:1000, Upstate Biotechnology, Lake
Placid, NY), phospho-ERK1/2 (1:2000), ERK1/2 (1:2000),
phospho-p38 (1:1000), p38 (1:1000), phospho-JNK1/2
(1:1000), JNK1/2 (1:1000), cyclin B1 (1:1000), cdc2
(1:1000), cleaved Caspase-3 (Asp175) (1:1000), cleaved
Caspase-8 (1:1000), cleaved Caspase-9 (Asp330)
(1:1000), PARP (46D11) (1:1000), phospho-Bcl-2 (ser70)
(1:1000), p53 (1:1000), were purchased from Cell Signal-
ing Technology, Inc. (Danvers, MA). After the PVDF
membrane was washed three times with TBS/0.2%
Tween 20 at room temperature, it was incubated with
appropriate secondary antibody (goat anti-mouse or
anti-rabbit, 1:10000, Sigma Chemical, St. Louis, MO)
labeled with horseradish peroxidase for 1 h at room
temperature. All proteins were detected using Western
Lightning™ Chemiluminescence Reagent Plus (Amer-
sham Biosciences, Arlington Heights, IL) and quantified
with densitometers.
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The viability of the cells after treatment with various
chemicals was evaluated using MTT assay preformed
in triplicate. Briefly, the LNCaP cells (2 × 10
5/well)
were incubated in 6-well plates containing 2 ml of
serum-containing medium. Cells were allowed to
adhere for 18-24 h and then were washed with phos-
phate-buffered saline (PBS). Solutions were always pre-
pared fresh by dissolving 0.2% DMSO (control) or
drugs in culture medium before their addition to
LNCaP cells. For inhibitor treatment experiments, cells
were pre-incubated for 1 h with 25 μMa n d5 0μM
ERK1/2 kinase inhibitor PD98059, 10 μMa n d2 0μM
p38k inhibitor SB203580, or 10 μMa n d2 0μMJ N K
inhibitor SP600125 and then were treated with 20 μM
isochaihulactone for 24 h. The drug-containing med-
ium was removed, cells were washed with PBS, and
culture medium containing 300 μg/ml MTT was added
for 1 h at 37°C. After the medium were removed, 2 ml
of DMSO were added to each well. Absorbance at 570
nm of the maximum was detected by a PowerWave ×
Microplate ELISA Reader (Bio-Tek Instruments,
Winooski, VT). The absorbance for DMSO-treated
cells was considered as 100%. The results were deter-
mined by three independent experiments.
Cell cycle analysis
The cell cycle was determined by flow cytometry fol-
lowing DNA staining to reveal the total amount of
DNA. Approximately 5 × 10
5 of LNCaP cells were
incubated with 20 μM isochaihulactone for the indi-
cated time. Cells were harvested with trypsin/EDTA,
collected, washed with PBS, fixed with cold 100% etha-
nol overnight, and then stained with a solution con-
taining 45 mg/ml PI, 10 mg/ml RNase A, and 0.1%
Triton X-100 for 1 h in the dark. The cells were then
passed through FACScan flow cytometer (equipped
with a 488-nm argon laser) to measure the DNA con-
tent. The data were obtained and analyzed with Cell-
Quest 3.0.1 (Becton Dickinson, Franklin Lakes, NJ) and
ModFitLT V2.0 software.
Transfection with siRNA
NAG-1 siRNA was designed by siGENOME SMART-
pool duplex siRNA and purchased from Dharmacon
RNAi Technologies (Chicago, IL). LNCaP cells at 50 to
60% confluence were transfected with NAG-1 siRNA
(10-50 nM) for 48 h using RNAifect Transfection
Reagent (QIAGEN). The medium was removed, and the
cells were treated with isochaihulactone or vehicle for
up to 48 h. Proteins were then isolated for western blot-
ting, or cells were collected for the MTT assay.
Immunocytochemistry
LNCaP cells cultured on glass slides were treated with
20 μM isochaihulactone for 48 h prior to fixation with
cold 4% paraformaldehyde. The fixed cells were washed
twice in PBS, and incubated in cold permeabilization
solution (0.3% Triton X-100 + 0.1% sodium citrate).
After endogenous peroxidase activity was inactivated
with 3% H2O2, the cells were washed with PBS and
incubated with an anti-cleaved caspase-3 at 4°C over-
night. The cells were washed with PBS three times and
then incubated with FITC-conjugated secondary anti-
body 1 h at room temperature. The cells were then
washed with PBS three times and stained with 300 nM
DAPI for 10 min. Images were obtained with a confocal
microscope (Carl Zeiss, Oberkochen, Germany).
TUNEL assay
LNCaP cells were cultured in the presence or absence of
isochaihulactone (20 μM) for 60 h and then examined
for apoptosis with TUNEL assay (In Situ Cell Death
Detection Kit, Roche).
Statistical analysis
T h ed a t aa r es h o w na sm e a n±S . D .S t a t i s t i c a ld i f f e r -
ences were analyzed using the Student’s t-test for nor-
mally distributed values and by nonparametric Mann-
Whitney U-test for values with a non-normal distribu-
tion. Values of P < 0.05 were considered significant.
Results
Isochaihulactone inhibited proliferation and induced
morphology changes of the human prostate cancer cells
Isochaihulactone has a strong anti-proliferative effect on
A549 cells and caused G2/M phase arrest and apoptosis
in a time- and concentration-dependent manner [7]. To
determine the cytotoxicity of isochaihulactone on pros-
tate cancer cells, three human prostate cancer cell lines,
namely, DU-145, PC3, and LNCaP were tested. The
MTT assay revealed that isochaihulactone had a strong
anti-proliferative effect on human prostate cancer cell
lines, especially the LNCaP cells (Figure 1A). LNCaP
cells were selected for subsequent studies. Compared
with untreated cells, isochaihulactone-treated LNCaP
cells showed obvious cell shrinkage and rounding up,
features typical of cells undergoing apoptosis (Figure 1B
and 1C). The MTT assay showed that isochaihulactone
had anti-proliferative effects on LNCaP cells that were
time- and dose-dependent (Figure 1D). Treatment of
LNCaP cells with 25 μM isochaihulactone for 48 h
resulted in 48.3% cell survival, whereas treatment for 72
h resulted in 32% cell survival (Figure 1D). Based on
these data, we used 20 μM isochaihulactone for
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Figure 1 Morphological changes and anti-proliferation effects after isochaihulactone treatment of prostate cancer cells.( A)H u m a n
prostate cancer cell lines DU-145, PC-3, LNCaP were treated with isochaihulactone from 6.25 to 50 μM at 48 h and analyzed with the MTT assay.
LNCaP cells were treated with 0.2% DMSO as a control (B)o r2 0μM isochaihulactone (C) for 24 h. LNCaP cells were treated with increasing
concentration of isochaihulactone from 3.125 to 50 μM at various times from 24 to 72 h and analyzed with the MTT assay (D). The data
represent the means ± S.D. from three independent experiments. **, P < 0.01 versus vehicle.
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ment and data not shown).
Isochaihulactone induced cell cycle arrest in G2/M phase
and changed the expression levels of G2/M regulatory
proteins
In order to elucidate its mode of action, we examined
effects of isochaihulactone on cell cycle progression.
Flow cytometry analysis showed that isochaihulactone
treatment resulted in the accumulation of cells in G2/M
phase in a time-dependent manner (Figure 2A). Quanti-
fication of proliferating untreated LNCaP cells showed
that 67.3% of cells were in the G0/G1 phase, 22.8% of
cells were in the S phase, and 9.7% of cells were in the
G2/M phase of cell cycle 48 h after plating. Treatment
of LNCaP cells with 20 μM isochaihulactone for 48 h
increased the percentage of cells in the G2/M phase to
40.2% and reduced the percentage of the cells in the
G 0 / G 1a n dSp h a s e( 5 1 . 1a n d8 . 6 % ,r e s p e c t i v e l y ) .T h e
subdiploid population of cells accounted for ~2%.
To determine the relationship between isochaihulac-
tone-induced mitotic arrest and p53, p21, cdc25c, and
cyclinB1/cdc2 activities and Bcl-2 phosphorylation, we
first examined the expression of these G2/M regulatory
proteins in LNCaP cells treated with 20 μMi s o c h a i h u -
lactone for increasing times. Western blot analysis
showed that treatment of LNCaP cells with isochaihu-
lactone resulted in upregulation of p53 and p21 and
downregulation of cdc25c, cyclin B1, and cdc2 in a
time-dependent manner (Figure 2B). These data suggest
that isochaihulactone apparently induced LNCaP cells to
undergo G2/M growth arrest by affecting the expression
of G2/M regulatory proteins.
Isochaihulactone induced LNCaP cell death
To evaluate the role of apoptosis in isochaihulactone-
induced cell death, caspase-3 staining and TUNEL stain-
ing were performed. After treatment with 20 μMi s o -
chaihulactone for 48 h, the LNCaP cells were fixed and
stained with anti-caspase 3, an increased number of
FITC-positive cells were seen (Figure 3B) as compared
to control cells (Figure 3A). To observe the late stage of
apoptosis, LNCaP cells treated with 20 μM isochaihulac-
tone for 60 h was collected and stained with TUNEL
staining kit. Most of the isochaihulactone-treated cells
were TUNEL positive (Figure 3D) as compared with
untreated cells (Figure 3C). Because activation of the
caspases and cleavage of PARP are crucial mechanisms
for induction of apoptosis, their involvement in isochai-
hulactone-induced cell death was investigated in LNCaP
cells. In addition, Bcl-2, which is located on the outer
mitochondrial membrane, is important for the suppres-
sion of mitochondrial manifestations of apoptosis [10].
We examined whether isochaihulactone-induced cell
death was associated with Bcl-2 phosphorylation. Cas-
pase-9 and caspase-3, but not caspase-8, were activated
after isochaihulactone treatment (Figure 3E). Thus, iso-
chaihulactone-induced cell death is mediated through a
caspase-dependent pathway. We also observed that cas-
pase-9 activation, Bcl-2 phosphorylation, and cleavage of
caspase-3 and PARP in a time-dependent manner (Fig-
ure 3E).
Isochaihulactone-induced JNK1/2 activation was followed
by growth inhibition of LNCaP cells
In our previous study, the anti-proliferative activity of
isochaihulactone in A549 cells was via ERK1/2, mito-
gen-activated protein kinase (MAPK) pathway. To
examine whether this pathway is activated in isochaihu-
lactone-treated LNCaP cells, cells were treated with iso-
chaihulactone for 48 h in the presence and absence of
B 
A 
Figure 2 Isochaihulactone apparently induces G2/M phase
arrest and changes the expression profiles of G2/M regulatory
proteins.( A) Isochaihulactone induced cell cycle arrest at G2/M in
LNCaP cells. For the cell cycle analysis, cells were seeded at 5 × 10
5
per 5-cm plate in triplicates and treated with 20 μM
isochaihulactone for 12-48 h. The data represent the means ± S.D.
from three different experiments. *, P < 0.05; **, P < 0.01; versus
control. (B) Cells were treated with 20 μM isochaihulactone for 6-72
h. Western blot analysis of p53, p21, cdc25c, cyclin B1 and cdc2 was
performed. b-actin was used as an internal control.
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Figure 3 Isochaihulactone induces cell death and initiates Bcl-2 phosphorylation and caspase activation in LNCaP cells.L N C a Pc e l l s
were treated with 0.2% DMSO (A)o r2 0μM isochaihulactone (B) for 48 h and then were fixed and stained for cleaved caspase-3. Nuclei were
stained with DAPI. LNCaP cells were treated with 0.2% DMSO (C)o r2 0μM isochaihulactone (D) for 60 h and then were fixed and stained with
the TUNEL assay. Nuclei were stained with DAPI. (E) Isochaihulactone induced caspase-9 activation, followed by Bcl-2 phosphorylation and then
caspase-3 activation. Cells were treated with 20 μM isochaihulactone for the indicated time and analysis by Western blotting. Membranes were
probed with caspase-8, phosphor-Asp330 caspase-9, phosphor-Ser70 Bcl-2, cleaved-baspase-3, PARP antibodies. b-actin was used as an internal
control.
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inhibitor SB203580 (10 or 20 μM), or the JNK1/2 inhibi-
tor SP600125 (10 or 20 μM). Only SP600125 signifi-
cantly blocked isochaihulactone-induced growth
inhibition in a concentration-dependent manner (Figure
4A). We also found that isochaihulactone had no effect
on the activation of ERK1/2 (Figure 4B) or PKC (data
not shown). Furthermore, to determine which JNK path-
ways were involved, we evaluated the effect of isochai-
hulactone on ERK1/2, p38, and JNK1/2 activation. We
found that only JNK1/2 showed increased phosphoryla-
tion after exposure of LNCaP cells to isochaihulactone
for 10-120 min (Figure 4B). In contrast, isochaihulac-
tone had no effect on the phosphorylation of p38 or
ERK1/2. To further clarify the role of JNK signaling
pathway in isochaihulactone-induced LNCaP cell death,
cell cycle analysis was performed in the presence or
absence of JNK inhibitor SP600125 by flow cytometry.
As shown in Figure 4C, the JNK inhibitor SP600125 (20
μM) significantly reduced the sub-G1 population
induced by isochaihulactone from 20.51% to 7.54%.
T h e s ed a t as u g g e s t e dt h a tJNK signaling pathway was
involved in the mechanism of isochaihulactone-induced
cell death.
Isochaihulactone induced EGR-1 and NAG-1 expression in
LNCaP cells
Recently, isochaihulactone was shown to upregulate
NAG-1 expression in the human lung carcinoma cell
line A549 through an ERK-dependent pathway involving
the activation of EGR-1 [9]. To evaluate whether EGR-1
and NAG-1 were involved in the anti-proliferative effect
of isochaihulactone in LNCaP cells, the expression of
EGR-1 and NAG-1 proteins was determined by western
blot analysis. After exposure of cells to isochaihulactone,
the expressions of both EGR-1 and NAG-1 were upre-
gulated in a time-dependent manner. EGR-1 was signifi-
cantly induced at 6 h after isochaihulactone treatment,
and this effect was maintained until 36 h. NAG-1
expression occurred later, with the highest expression at
60-72 h (Figure 5A).
The JNK1/2 signaling pathway was involved in
isochaihulactone-induced NAG-1 expression
T oi n v e s t i g a t eap o s s i b l er o l ef o rJ N K 1 / 2i nt h er e g u l a -
tion of NAG-1 expression, LNCaP cells were treated
with isochaihulactone (20 μM )i nt h ep r e s e n c ea n d
absence of the p38 inhibitor SB203580 (20 μM), the
JNK1/2 inhibitor SP600125 (20 μM), or the MEK1/2
inhibitor PD98059 (50 μM). Using western blot analysis,
we found that inhibition of JNK1/2 expression with
SP600125 reduced NAG-1 protein levels after treatment
of LNCaP cells with isochaihulactone (Figure 5B). In
contrast, inhibition of ERK1/2 or p38 had no effect on
the induction of NAG-1 (Figure 5B). These results sug-
gest that activation of the JNK1/2 signaling pathway was
involved in isochaihulactone-induced NAG-1 expression.
Induction of NAG-1 was involved in isochaihulactone-
induced LNCaP cell death
Since the expressions of EGR-1 and NAG-1 were
observed in isochaihulactone-induced A549 apoptotic
cell death, their roles in LNCaP cell death were investi-
gated. To determine the role of NAG-1 in the antican-
cer potential of isochaihulactone in prostate cancer, we
used an siRNA approach. Western blot analysis con-
firmed the suppression of NAG-1 by NAG-1 siRNA in a
concentration-dependent manner (Figure 5C). To
further characterize the role of NAG-1 in isochaihulac-
tone-induced growth inhibition, LNCaP cells were trans-
fected with siNAG-1 siRNA for 48 h. Then, the MTT
assay was performed to determine the percentage of cell
death 48 h after treatment with 20 μM isochaihulactone.
Nineteen and 24% of cell death was inhibited by 20 and
40 nM NAG-1 siRNA, respectively, after exposure of
cells to 20 μM isochaihulactone (Figure 5D). Thus, iso-
chaihulactone-induced cell death in LNCaP cells
occurred partially through NAG-1 activation.
Discussion
In our previous study, we demonstrated that isochaihu-
lactone was efficacious against various models of human
solid tumors but not prostate cancer [7]. We also have
shown recently that isochaihulactone triggers an apopto-
tic pathway in human A549 lung cancer cells that
occurs via the ERK1/2 and NAG-1 pathway [9]. To clar-
ify the mechanisms of isochaihulactone-induced tumor
apoptosis between different types of cancer cells, we
further investigated the antitumor potential and
mechanisms of isochaihulactone action in human pros-
tate cancer cells. Three human prostate cell lines were
used to test the cytotoxicity of isochaihulactone, only
the LNCaP prostate cancer cells showed sensitivity to
isochaihulactone treatment. This phenomenon might be
important to the antitumor potential of isochaihulactone
and is discussed later.
In this study, we demonstrated that isochaihulactone
apparently induced G2/M cell cycle arrest and cell death
in LNCaP cells. The tumor suppressor protein p53 plays
ar o l ei nt h em o l e c u l a rr e s p o n s et oD N Ad a m a g ea n d
cell cycle arrest. The cyclin-dependent kinase inhibitor
p21 also helps to maintain G2/M cell cycle arrest by
inactivating the cyclin B1/cdc2 complex, disrupting the
interaction between proliferating cell nuclear antigen
and cdc25c [11]. Our result showed that increased levels
of p53 and p21 proteins were expressed in LNCaP cells
in response to treatment with isochaihulactone (Figure
2B). The transition from G2 phase to mitosis is
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Figure 4 Growth inhibition of LNCaP cells induced by isochaihulactone is partially rescued by JNK1/2 inhibitor.( A) MTT assay of LNCaP
cells pretreated with p38 inhibitor SB203580 (10 or 20 μM), the JNK1/2 inhibitor SP600125 (10 or 20 μM) or the ERK1/2 inhibitor PD98059 (25 or
50 μM) for 1 h and then treated with 20 μM of isochaihulactone for 48 h. The values are the mean ± S.D. from three independent experiments
performed in duplicate. (B) Cells were treated with 20 μM isochaihulactone for the indicated times. Phospho-ERK1/2, total-ERK1/2, phospho-JNK,
total-JNK, phospho-38, total-p38 were detected by western blotting. (C) Cells were treated with 20 μM isochaihulactone for 48 h in the presence
or absence of JNK1/2 inhibitor SP600125 (20 μM). Cell cycle analysis was done as described in Methods. Isochaihulactone-induced sub-G1
population (20.51%) was decreased by JNK1/2 inhibitor SP600125 pre-treatment (7.54%). The data represent the means ± S.D. from three
independent experiments. **, P <0.01; ***, P < 0.001 versus vehicle.
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Figure 5 Isochaihulactone induces NAG-1 expression via JNK1/2 activation, and isochaihulactone-induced cell death can be rescued
by NAG-1 siRNA transfection.( A) Expression of EGR-1 and NAG-1 after treatment of LNCaP cells with 20 μM isochaihulactone for the indicated
times. (B) NAG-1 expression of LNCaP cells pretreated with the p38 inhibitor SB203580 (20 μM), the JNK1/2 inhibitor SP600125 (20 μM), or the
MEK1/2 inhibitor PD98059 (50 μM) for 1 h and then treated with 20 μM isochaihulactone for 24 h. (C) Suppression of isochaihulactone-induced
NAG-1 expression in LNCaP cells by NAG-1 siRNA transfection. LNCaP cells were transfected with scramble siRNA (
#) or 20 nM, 40 nM NAG-1
siRNA for 48 h using the RNAifect transfection reagent followed by treatment with 20 μM isochaihulactone for 48 or 72 h. Western blot analysis
was performed for NAG-1. (D) Isochaihulactone-induced anti-proliferative activity was measured with the MTT assay in LNCaP cells transfected
with scramble (
#) or NAG-1 siRNA for 48 h and then treated with 20 μM isochaihulactone for 48 h. The data represent the means ± S.D. from
three independent experiments. ***, P < 0.001 versus vehicle.
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B1/cdc2 complex. Cyclin B1/cdc2 activation is triggered
when cdc25c dephosphorylates Thr15 [12,13]. In our
study, isochaihulactone-mediated LNCaP cell cycle
arrest at G2/M phase (Figure 2B) was accompanied by
decreased expression of cyclin B1 and cdc2 kinase. The
decrease in the levels of cdc2 may be due to the
decrease in cdc25 activation by phosphorylation, leading
to subsequent G2 arrest (Figure 2B).
Activation of aspartate-specific cysteine protease (cas-
pase) represents a crucial step in the induction of drug-
induced apoptosis, and cleavage of PARP by caspase-3 is
considered to be one of the hallmarks of apoptosis [14].
Isochaihulactone-induced caspase 3 cleavage was
observed by immunocytochemistry (Figure 3B), and
late-stage apoptosis was revealed by TUNEL staining
(Figure 3D). Furthermore, isochaihulactone inhibited
Bcl-2 expression, induced caspase-9 and caspase-3 clea-
vage, and induced PARP activation were also observed
(Figure 3E). It is interesting to note that isochaihulac-
tone-induced Bcl-2 phosphorylation, caspase-9 cleavage,
and PARP cleavage were observed at nearly the same
time point, suggesting that the isochaihulactone-induced
Bcl-2 phosphorylation is related apoptosis (Figure 3E).
Recent reports have revealed the involvement of JNK-
mediated Bcl-2 phosphorylation and degradation, and
also the activation of caspase-9 in the apoptosis of both
the androgen-dependent and -independent human pros-
tate cancer cells [15]. Bcl-2 and Bcl-XL inhibit apoptosis
by regulating the mitochondrial membrane potential,
whereas cytochrome c release is required for activation
of caspase-9 and subsequent activation of caspase-3
[16]. Thus, increased levels of Bcl-2 phosphorylation,
caspase-9 and -3 activation appeared to correlate with
mitochondrial apoptosis in isochaihulactone-induced
LNCaP cell death.
Many microtubule-destabilizing agents are activators
of caspase-9, a major key player in mitochondrial apop-
totic pathway [17,18]. Microtubule depolymerization
agents arrest the cell cycle in G2/M phase by acting
through several types of kinases, which lead to phos-
phorylation cascades, activation of the cyclin B1/cdc2
complex, and the phosphorylation of Bcl-2 [19]. The
MAPK inhibitor PD98059 has been shown to partially
inhibit isochaihulactone-induced cdc2 phosphorylation,
causing G2/M arrest in A549 cells. The activation of
NAG-1 expression via ERK1/2 pathway is involved in
isochaihulactone-induced G2/M arrest in A549 cells
[7,9]. To determine which MAPK family member is
involved in the major signaling pathway for isochaihu-
lactone-mediated cell growth inhibition, MAPK inhibi-
tors were used to study the growth inhibition induced
by isochaihulactone in LNCaP cells. Only JNK1/2 inhibi-
tor SP600125 significantly decreased the growth
inhibition induced by isochaihulactone (Figure 4A), and
neither the p38 inhibitor SB203580 nor the ERK1/2
inhibitor PD98059 reversed isochaihulactone-induced
growth inhibition. Phosphorylation of JNK kinase was
also observed with western blot analysis after isochaihu-
lactone treatment (Figure 4B). In cell cycle analysis, pre-
treatment of JNK1/2 inhibitor SP600125 significantly
reduces sub-G1 population (Figure 4C). These data sug-
gest that JNK1/2 signaling pathway is involved in iso-
chaihulactone-induce cell death.
Increased NAG-1 expression results in the induction
of apoptosis in several cancer cell lines [20,21]. NAG-1
is induced not only by NSAIDs but also by several anti-
tumorigenic compounds including dietary compounds,
peroxisome proliferator-activated receptor-g ligands,
phytochemicals [16-18], as well as resveratrol, genistein,
diallyldisulfide, 5F203, and retinoid 6-[3-(1-adamantyl)-
4-hydroxyphenyl]-2-naphthalene carboxylic acid
(AHPN) [22-24]. NAG-1 appears to be a key down-
stream target of EGR-1[9].
In our previously studies, we confirmed the antitumor
effect of isochaihulactone [7], and the inhibition of
tumor growth that was attributable to NAG-1 protein
e x p r e s s i o ni nan u d em i c ex e n o g r a f tm o d e l[ 9 ] .T h u s ,
NAG-1 is an essential factor in the antitumor activity of
isochaihulactone. Our current results show that isochai-
hulactone induced EGR-1 and NAG-1 protein expres-
sion in LNCaP cells in a time-dependent manner
(Figure 5A). Furthermore, only the JNK1/2 inhibitor
SP600125 reduced isochaihulactone-induced NAG-1
protein expression (Figure 5B). These data support that
isochaihulactone-induced JNK1/2 activity is critical in
regulating NAG-1 expression. In addition, we further
confirmed by using siRNA approach that NAG-1
expression has an apoptosis-promoting effect (Figure
5D).
In summary, we found that isochaihulactone increased
NAG-1 expression, suggesting that the antitumor effect
of isochaihulactone is mediated via this tumor suppres-
sor protein. NAG-1 mRNA is highly expressed in the
human prostate epithelium [25], suggesting its role in
prostate homeostasis. Despite this, NAG-1 negatively
affects LNCaP cell survival [26], and is overexpressed in
many tumors including prostate cancer [27,28]. NAG-1
may be like other members of the TGF-b superfamily,
acting as a tumor suppressor in the early stages but
becoming pro-tumorigenic during the later stages of
tumor progression. The effects of NAG-1 appear to be
ambiguous, and under different conditions, NAG-1 exhi-
bits either tumorigenic or anti-tumorigenic activity [24].
Epidemiological studies have shown that patients who
use NSAIDs for 10-15 years have a reduced risk of
developing cancer [29]. NSAIDs inhibit cyclooxygenase-
1 (COX-1) and cyclooxygenase-2 (COX-2). Several
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tumorigenic activity of NAG-1 may be due to the inter-
action of NAG-1 and cyclooxygenase [21,30,31].
Recent study has revealed a new pathway that Retino-
blastoma (RB; encoded by RB1)d e p l e t i o ni n d u c e d
unchecked androgen receptor (AR) activity that under-
pinned therapeutic bypass and tumor progression [32].
The hypo-phosphorylation form of RB suppresses E2F1-
mediated transcriptional activation and induces cell
cycle arrest. Loss of RB1 was observed in most of the
castrate-resistant prostate cancer (CRPC), and AR as a
gene under the control of E2F1, which in turn is strin-
gently regulated by RB. Since hypo-phosphorylation of
RB was observed after isochaihulactone treatment in
LNCaP cells (data not shown), this might explain why
LNCaP is more sensitive to isochaihulactone than the
other two androgen-independent prostate cancer cell
lines. However, the exact mechanism of these differ-
ences needs to be extensively investigated.
Conclusions
Our current study provides information on the pro-
apoptotic and anti-tumorigenic activity of isochaihulac-
tone in human LNCaP prostate cancer cell line. Isochai-
hulactone downregulated expression of G2/M regulatory
proteins including cyclin B1, cdc2, cdc25c, apparently
resulting G2/M cell cycle arrest. In addition, isochaihu-
lactone-induced cell death was caspase-dependent and
occurred through activations of caspase-9 and caspase-3.
The JNK1/2 MAPK signaling pathway and NAG-1
expression were implicated in isochaihulactone-induced
cell death. These findings suggest that isochaihulactone
has a high therapeutic potential for prostate cancer and
should be extensively investigated with in vivo studies.
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